

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:27:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    119 TO ITERATE

100.0% PROCESSED     119 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1726 TO     3034
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 17:27:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   2285 TO ITERATE

100.0% PROCESSED    2285 ITERATIONS                               42 ANSWERS
SEARCH TIME: 00.00.01

L3           42 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               148.15     148.36

FILE 'CAPLUS' ENTERED AT 17:27:24 ON 10 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:717059 CAPLUS
DOCUMENT NUMBER: 137:247710
TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625

PRIORITY APPLN. INFO.: US 2000-214983P P 20000629
OTHER SOURCE(S): MARPAT 137:247710
GI



AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.
IT **388117-63-3P 388117-64-4P 388117-65-5P**
388117-66-6P 388117-67-7P 388117-68-8P
388117-69-9P 388117-70-2P 388117-71-3P
388117-72-4P 388117-73-5P 388117-74-6P
388117-75-7P 388117-76-8P 388117-77-9P
388117-78-0P 388117-79-1P 388117-80-4P
388117-81-5P 388117-82-6P 388117-83-7P
388117-84-8P 388117-85-9P 388117-86-0P
388117-87-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
antiinflammatory and immunosuppressive agents)
RN 388117-63-3 CAPLUS
CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS
CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS
CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS
CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-67-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-68-8 CAPLUS
CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-70-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-71-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-72-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-79-1 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-76-8 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388117-84-8 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-85-9 CAPLUS
CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 388117-86-0 CAPLUS
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **388118-57-8P 388118-58-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflammatory and immunosuppressive agents)

RN 388118-57-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS
CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:449662 CAPLUS
DOCUMENT NUMBER: 137:33310
TITLE: Preparation of anilinopyrimidines as IKK inhibitors
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020195	A5	20020618	AU 2002-20195	20011205

PRIORITY APPLN. INFO.: US 2000-251816P P 20001206
WO 2001-US46403 W 20011205
OTHER SOURCE(S): MARPAT 137:33310
GI



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.

IT **434944-90-8P 434945-04-7P 434945-05-8P 434945-27-4P 434950-45-5P 434950-46-6P**

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434950-47-7P 434950-48-8P 434950-49-9P
434950-50-2P 434950-51-3P 434950-52-4P
434950-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anilinopyrimidines as IKK inhibitors)
RN 434944-90-8 CAPLUS
CN Benzamide, 4-[[4-[[4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-05-8 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-27-4 CAPLUS
CN Morpholine, 4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 434950-48-8 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-49-9 CAPLUS
CN Piperazine, 1-methyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-45-5 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449661 CAPLUS
DOCUMENT NUMBER: 137:33309
TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205

OTHER SOURCE(S): MARPAT 137:33309
GI



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 10 .mu.M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-45-5 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-48-8 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
contg. one or more compds. of the above compds.
IT **434944-90-8P 434945-04-7P 434945-05-8P**
434945-27-4P 434950-45-5P 434950-46-6P
434950-47-7P 434950-48-8P 434950-49-9P
434950-50-2P 434950-51-3P 434950-52-4P
434950-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anilinopyrimidines as JNK pathway inhibitors)
RN 434944-90-8 CAPLUS
CN Benzamide, 4-[[4-[4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-05-8 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-27-4 CAPLUS
CN Morpholine, 4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-49-9 CAPLUS
CN Piperazine, 1-methyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:31429 CAPLUS
DOCUMENT NUMBER: 136:102394
TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert
PATENT ASSIGNEE(S): Abbott Lab., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-606717 A 20000629
WO 2001-US20128 W 20010622
OTHER SOURCE(S): MARPAT 136:102394
GI



AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SHwas etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT 388118-57-8P 388118-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388118-57-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS
CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388117-63-3P 388117-64-4P 388117-65-5P
388117-66-6P 388117-67-7P 388117-68-8P
388117-69-9P 388117-70-2P 388117-71-3P
388117-72-4P 388117-73-5P 388117-74-6P
388117-75-7P 388117-76-8P 388117-77-9P
388117-78-0P 388117-79-1P 388117-80-4P
388117-81-5P 388117-82-6P 388117-83-7P
388117-84-8P 388117-85-9P 388117-86-0P
388117-87-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-63-3 CAPLUS
CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS
CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS
CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS
CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-67-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 388117-68-8 CAPLUS
CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-70-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-76-8 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-71-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-72-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-73-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-79-1 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-86-0 CAPLUS
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388117-87-1 CAPLUS
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.



RN 388117-84-8 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388117-85-9 CAPLUS
CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:612432 CAPLUS
DOCUMENT NUMBER: 117:212432
TITLE: Studies on cerebral protective agents. I. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities
AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshie; Katsuta, Kiyotaka; Kamitani, Toshiharu; Takasugi, Hisashi
CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1992), 40(6), 1452-61
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Novel 4-arylpyrimidine derivs. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O2NC6H4) has ALP activity (73% inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of vitamin E.
IT **103293-67-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antianoxic and antilipid peroxidn. activities of)
RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1986:572492 CAPLUS
DOCUMENT NUMBER: 105:172492
TITLE: Pyrimidine derivatives
INVENTOR(S): Takaya, Takao; Takasugi, Hisashi; Kuno, Atsushi; Sugiyama, Yoshie
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 192 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
FI 8502796	A	19860120	FI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
FI 8503698	A	19860402	FI 1985-3698	19850926
EP 177287	A2	19860409	EP 1985-306880	19850927
EP 177287	A3	19861126		
EP 177287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58897	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001

PRIORITY APPLN. INFO.:

GB 1984-18380	19840719
GB 1984-24711	19841001
GB 1985-9623	19850415
GB 1985-9633	19850415
EP 1985-305143	19850718
EP 1985-306880	19850927

GI

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



I II

AB Pyrimidines I (R = substituted aryl; R1 = CO2H, esterified CO2H, alkanoyl, etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prepd., and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine deriv. II was heated with MnO2 to give I (R = 4-pyridyl, R1 = CO2Et, R2 = Me, R3 = Ph). II was prepd. from an .alpha.-(arylmethylene)acetoacetate ester and an amidine.

IT **103293-67-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of cerebrovascular disease)

RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.63	175.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.91	-3.91

STN INTERNATIONAL LOGOFF AT 17:27:58 ON 10 APR 2003

Narrow search

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09888840narrow.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:17:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 10:18:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 10:18:08 ON 08 APR 2003

FILE COVERS 1907 - 8 Apr 2003 VOL 138 ISS 15
FILE LAST UPDATED: 7 Apr 2003 (20030407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:717059 CAPLUS
DOCUMENT NUMBER: 137:247710
TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983P P	20000629

OTHER SOURCE(S): MARPAT 137:247710
GI



I



II

AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.

IT **388117-75-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31429 CAPLUS

DOCUMENT NUMBER: 136:102394

TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents

INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S): Abbott Lab., USA

SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294704 A1 20030326 EP 2001-946705 20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-606717 A 20000629
WO 2001-US20128 W 20010622

OTHER SOURCE(S): MARPAT 136:102394

GI



I

AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SHwas etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT **388117-75-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	9.49	157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 10:18:32 ON 08 APR 2003

Broad Search



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:33:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2803 TO ITERATE

 35.7% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        52886 TO    59234
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 17:33:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  55054 TO ITERATE

100.0% PROCESSED   55054 ITERATIONS                              107 ANSWERS
SEARCH TIME: 00.00.02

L3          107 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             148.15     148.36

FILE 'CAPLUS' ENTERED AT 17:33:50 ON 10 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 6 L3

=> d ibib abs histr tot
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and

its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:717059 CAPLUS
DOCUMENT NUMBER: 137:247710
TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983P P	20000629
OTHER SOURCE(S):		MARPAT 137:247710		

GI



AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.

IT **388117-63-3P 388117-64-4P 388117-65-5P 388117-66-6P 388117-67-7P 388117-68-8P 388117-69-9P 388117-70-2P 388117-71-3P 388117-72-4P 388117-73-5P 388117-74-6P 388117-75-7P 388117-76-8P 388117-77-9P 388117-78-0P 388117-79-1P 388117-80-4P 388117-81-5P 388117-82-6P 388117-83-7P 388117-84-8P 388117-85-9P 388117-86-0P 388117-87-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-67-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-68-8 CAPLUS
CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
antiinflammatory and immunosuppressive agents)

RN 388117-63-3 CAPLUS
CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS
CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS
CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS
CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-70-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-71-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-72-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 388117-79-1 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-76-8 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388117-84-8 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-85-9 CAPLUS
CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 388117-86-0 CAPLUS
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **388118-57-8P 388118-58-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflammatory and immunosuppressive agents)
RN 388118-57-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS
CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:449662 CAPLUS
DOCUMENT NUMBER: 137:33310
TITLE: Preparation of anilinopyrimidines as IKK inhibitors
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020195	A5	20020618	AU 2002-20195	20011205
PRIORITY APPLN. INFO.:			US 2000-251816P P	20001206
			WO 2001-US46403 W	20011205
OTHER SOURCE(S):		MARPAT 137:33310		

GI



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.

IT **434944-90-8P 434944-91-9P 434944-92-0P 434944-96-4P 434944-99-7P 434945-00-3P**

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434945-01-4P 434945-04-7P 434945-05-8P
434945-27-4P 434945-75-2P 434945-76-3P
434949-28-7P 434949-29-8P 434949-31-2P
434949-33-4P 434949-35-6P 434949-36-7P
434949-38-9P 434949-40-3P 434949-42-5P
434949-44-7P 434949-47-0P 434949-50-5P
434949-53-8P 434949-56-1P 434949-68-5P
434949-71-0P 434949-74-3P 434949-77-6P
434949-79-8P 434949-81-2P 434949-83-4P
434949-85-6P 434949-87-8P 434949-92-4P
434949-94-7P 434949-95-8P 434949-96-9P
434949-97-0P 434949-98-1P 434949-99-2P
434950-03-5P 434950-04-6P 434950-05-7P
434950-06-8P 434950-07-9P 434950-08-0P
434950-09-1P 434950-10-4P 434950-11-5P
434950-12-6P 434950-13-7P 434950-14-8P
434950-15-9P 434950-33-1P 434950-34-2P
434950-35-3P 434950-36-4P 434950-37-5P
434950-38-6P 434950-39-7P 434950-40-0P
434950-41-1P 434950-42-2P 434950-43-3P
434950-44-4P 434950-45-5P 434950-46-6P
434950-47-7P 434950-48-8P 434950-49-9P
434950-50-2P 434950-51-3P 434950-52-4P
434950-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anilinopyrimidines as IKK inhibitors)

RN 434944-90-8 CAPLUS
CN Benzamide, 4-[[4-[4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS
CN Benzamide, 4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-92-0 CAPLUS
CN Benzamide, 4-[[4-[4-(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-96-4 CAPLUS
CN Benzamide, 4-[[4-[4-(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS
CN Benzamide, 4-[[4-[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-00-3 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzamide, 4-[[4-[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7
CMF C23 H25 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 434945-01-4 CAPLUS
CN Benzamide, 4-[[4-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434945-05-8 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-27-4 CAPLUS
CN Morpholine, 4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-76-3 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-28-7 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-31-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-33-4 CAPLUS
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434949-40-3 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS
CN Piperidine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
NAME)



RN 434949-35-6 CAPLUS
CN Piperazine, 3-methyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434949-36-7 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-38-9 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A

RN 434949-44-7 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-47-0 CAPLUS
CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
NAME)



RN 434949-50-5 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-53-8 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 434949-56-1 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX
NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434949-68-5 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-[[4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-71-0 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[[4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS
CN Piperazine, 1-[4-[[4-[4-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-77-6 CAPLUS
CN Piperidine, 1-[4-[[4-[4-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 434949-79-8 CAPLUS
CN Piperazine,
1-acetyl-4-[4-[[4-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-81-2 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 434949-83-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[4-[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 434949-85-6 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-87-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-91-4 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-94-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-99-2 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-04-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-05-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-95-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-97-0 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-98-1 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 434950-06-8 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-07-9 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-08-0 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-09-1 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-10-4 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 434950-14-8 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-15-9 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-33-1 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-11-5 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-12-6 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-34-2 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-35-3 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



RN 434950-36-4 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-38-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434950-43-3 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-44-4 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS
CN Piperazine, 3-methyl-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434950-40-0 CAPLUS
CN Piperidine, 4-(1-pyrrolidinyl)-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-41-1 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-42-2 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-45-5 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-48-8 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS
CN Piperazine, 1-methyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzoic acid, 4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT **434950-65-9P 434950-68-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of anilinopyrimidines as IKK inhibitors)
RN 434950-65-9 CAPLUS
CN Benzoic acid, 4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449661 CAPLUS
DOCUMENT NUMBER: 137:33309
TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002027214	A5	20020618	AU 2002-27214	20011205

PRIORITY APPLN. INFO.: US 2000-251904P P 20001206
WO 2001-US46402 W 20011205
OTHER SOURCE(S): MARPAT 137:33309
GI



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 10 .mu.M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.
IT **434944-90-8P 434944-91-9P 434944-92-0P 434944-96-4P 434944-99-7P 434945-00-3P**

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
434945-01-4P 434945-04-7P 434945-05-8P
434945-27-4P 434945-75-2P 434945-76-3P
434949-28-7P 434949-29-8P 434949-31-2P
434949-33-4P 434949-35-6P 434949-36-7P
434949-38-9P 434949-40-3P 434949-42-5P
434949-44-7P 434949-47-0P 434949-50-5P
434949-53-8P 434949-56-1P 434949-68-5P
434949-71-0P 434949-74-3P 434949-77-6P
434949-79-8P 434949-81-2P 434949-83-4P
434949-85-6P 434949-87-8P 434949-91-4P
434949-94-7P 434949-95-8P 434949-96-9P
434949-97-0P 434949-98-1P 434949-99-2P
434950-03-5P 434950-04-6P 434950-05-7P
434950-06-8P 434950-07-9P 434950-08-0P
434950-09-1P 434950-10-4P 434950-11-5P
434950-12-6P 434950-13-7P 434950-14-8P
434950-15-9P 434950-33-1P 434950-34-2P
434950-35-3P 434950-36-4P 434950-37-5P
434950-38-6P 434950-39-7P 434950-40-0P
434950-41-1P 434950-42-2P 434950-43-3P
434950-44-4P 434950-45-5P 434950-46-6P
434950-47-7P 434950-48-8P 434950-49-9P
434950-50-2P 434950-51-3P 434950-52-4P
434950-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anilinopyrimidines as JNK pathway inhibitors)

RN 434944-90-8 CAPLUS
CN Benzamide, 4-[[4-[4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS
CN Benzamide, 4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzamide, 4-[[4-[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7
CMF C23 H25 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 434945-01-4 CAPLUS
CN Benzamide, 4-[[4-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylthio)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434944-92-0 CAPLUS
CN Benzamide, 4-[[4-[4-(2-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-96-4 CAPLUS
CN Benzamide, 4-[[4-[4-(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS
CN Benzamide, 4-[[4-[4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-00-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434945-05-8 CAPLUS
CN Benzamide, 4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-27-4 CAPLUS
CN Morpholine, 4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-76-3 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-28-7 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-31-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-33-4 CAPLUS
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
NAME)



RN 434949-35-6 CAPLUS
CN Piperazine, 3-methyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434949-36-7 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-38-9 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434949-40-3 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS
CN Piperidine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A

RN 434949-44-7 CAPLUS
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-47-0 CAPLUS
CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
NAME)



RN 434949-50-5 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-53-8 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 434949-56-1 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX
NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434949-68-5 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-71-0 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-77-6 CAPLUS
CN Piperidine, 1-[4-[[4-[4-[(4-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 434949-79-8 CAPLUS
CN Piperazine,
1-acetyl-4-[4-[[4-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-81-2 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 434949-83-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[4-[2-[[4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 434949-85-6 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-87-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-91-4 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-94-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-99-2 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(1-piperazinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-04-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-05-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434949-95-8 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-97-0 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-98-1 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 434950-06-8 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-07-9 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-08-0 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-09-1 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-10-4 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS
CN Piperazine, 3,5-dimethyl-1-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 434950-14-8 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-15-9 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-33-1 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-11-5 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(1-pyrrolidinylsulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-12-6 CAPLUS
CN 1-Piperazineethanamine, N,N-dimethyl-4-[4-[[4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-34-2 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-35-3 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



RN 434950-36-4 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-38-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 434950-43-3 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-44-4 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS
CN Piperazine, 3-methyl-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434950-40-0 CAPLUS
CN Piperidine, 4-(1-pyrrolidinyl)-1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-41-1 CAPLUS
CN 4-Piperidinol, 1-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-42-2 CAPLUS
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-45-5 CAPLUS
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-48-8 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS
CN Piperazine, 1-methyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS
CN Piperazine, 1-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 434950-51-3 CAPLUS
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzoic acid, 4-[[4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT **434950-65-9P 434950-68-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of anilinopyrimidines as JNK pathway inhibitors)
RN 434950-65-9 CAPLUS
CN Benzoic acid, 4-[[4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434950-68-2 CAPLUS

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:31429 CAPLUS
DOCUMENT NUMBER: 136:102394
TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert
PATENT ASSIGNEE(S): Abbott Lab., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-606717 A 20000629
WO 2001-US20128 W 20010622
OTHER SOURCE(S): MARPAT 136:102394
GI



I

AB Title compds. were prepd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SHwas etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT **388118-57-8P 388118-58-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflammatory and immunosuppressive agents)
RN 388118-57-8 CAPLUS

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 4(1H)-Pyrimidinone, 6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS
CN Pyrimidine, 4-chloro-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388117-63-3P 388117-64-4P 388117-65-5P
388117-66-6P 388117-67-7P 388117-68-8P
388117-69-9P 388117-70-2P 388117-71-3P
388117-72-4P 388117-73-5P 388117-74-6P
388117-75-7P 388117-76-8P 388117-77-9P
388117-78-0P 388117-79-1P 388117-80-4P
388117-81-5P 388117-82-6P 388117-83-7P
388117-84-8P 388117-85-9P 388117-86-0P
388117-87-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting
antiinflammatory and immunosuppressive agents)
RN 388117-63-3 CAPLUS
CN Morpholine, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS
CN 4-Piperidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS
CN Morpholine, 2,6-dimethyl-4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS
CN 3-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-67-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-68-8 CAPLUS
CN Acetamide, N-ethyl-N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 388117-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-70-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-71-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-72-4 CAPLUS
CN 1-Piperazineacetic acid, 4-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-73-5 CAPLUS
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-74-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-75-7 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-76-8 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-80-4 CAPLUS
CN 3-Piperidinemethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS
CN 4-Piperidineethanol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-82-6 CAPLUS
CN Acetamide, N-[1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-77-9 CAPLUS
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-78-0 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-79-1 CAPLUS
CN Pyrimidine, 4-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388117-84-8 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-85-9 CAPLUS
CN Carbamic acid, [1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 388117-86-0 CAPLUS
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:612432 CAPLUS
DOCUMENT NUMBER: 117:212432
TITLE: Studies on cerebral protective agents. I. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities
AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshie; Katsuta, Kiyotaka; Kamitani, Toshiharu; Takasugi, Hisashi
CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1992), 40(6), 1452-61
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Novel 4-arylpyrimidine derivs. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl) has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O2NC6H4) has ALP activity (73% inhibition at 10-5 g/mL). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of vitamin E.

IT 103293-67-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antianoxic and antilipid peroxidn. activities of)

RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:572492 CAPLUS
DOCUMENT NUMBER: 105:172492
TITLE: Pyrimidine derivatives
INVENTOR(S): Takaya, Takao; Takasugi, Hisashi; Kuno, Atsushi; Sugiyama, Yoshie
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 192 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
FI 8502796	A	19860120	FI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
FI 8503698	A	19860402	FI 1985-3698	19850926
EP 177287	A2	19860409	EP 1985-306880	19850927
EP 177287	A3	19861126		
EP 177287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58897	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001

PRIORITY APPLN. INFO.:
GB 1984-18380 19840719
GB 1984-24711 19841001
GB 1985-9623 19850415
GB 1985-9633 19850415
EP 1985-305143 19850718
EP 1985-306880 19850927

G1

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Pyrimidines I (R = substituted aryl; R1 = CO2H, esterified CO2H, alkanoyl, etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prepd., and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine deriv. II was heated with MnO2 to give I (R = 4-pyridyl, R1 = CO2Et, R2 = Me, R3 = Ph). II was prepd. from an .alpha.-(arylmethylene)acetoacetate ester and an amidine.

IT **103293-67-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of cerebrovascular disease)

RN 103293-67-0 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[2-[(4-chlorophenyl)thio]phenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	28.05	176.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.91	-3.91

STN INTERNATIONAL LOGOFF AT 17:34:56 ON 10 APR 2003